newsfilter
← Latest News
PR Newswire·

Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit

  • Compugen Ltd. announced an oral presentation at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Europe in Lisbon, Portugal, scheduled for November 16-19, 2026.
  • The presentation titled "UnigenX™: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation" will occur on Wednesday, November 18, 2026, at 18:30 GMT.
  • Dr. Roy Granit, Head of Computational Discovery at Compugen, will present on UnigenX™, an expansion of the company's AI platform focused on targeted immune activation modalities like T cell engagers.
  • Compugen's clinical pipeline includes COM701, an anti-PVRIG antibody currently in the MAIA-ovarian adaptive platform trial for relapsed ovarian cancer.
  • Rilvegostomig, a PD-1/TIGIT bispecific antibody, is being developed by AstraZeneca under an exclusive license agreement & evaluated across multiple Phase 3, Phase 2, & Phase 1 clinical trials.
  • GS-0321 (previously COM503), an IL-18 binding protein blocker, is licensed to Gilead & is currently undergoing a Phase 1 trial conducted by Compugen.
  • Compugen's shares trade under the ticker symbol CGEN on both the Nasdaq & Tel Aviv Stock Exchange.
Company
Compugen Ltd.
Keywords
Compugen Ltd.